Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618156 | 0.99 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618161 | 0.97 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618163 | 0.95 | MEN1 (0.37) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17231588 | 0.94 | MEN1 (0.37) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618160 | 0.93 | MEN1 (0.38) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618159 | 0.93 | MEN1 (0.38) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618158 | 0.93 | MEN1 (0.41) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618116 | 0.92 | MEN1 (0.34) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17618126 | 0.91 | KMT2A (0.35) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL17369025 | 0.91 | KMT2A (0.38) | MEN1KMT2AMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160087215-A1 | NOVEL PYRIMIDINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES | HODOGAYA CHEMICAL CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160087215-A1 | NOVEL PYRIMIDINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES | HODOGAYA CHEMICAL CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160087215-A1 | NOVEL PYRIMIDINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES | SLC29A1, SLC29A2, DHX29 | MEN1 2846/4885KMT2A 2216/4885MAPT 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.